Marksans Pharma Ltd. announced its audited financial results for the quarter and full year ended March 31, 2026, marking a milestone year with historic triple performance. The company achieved its highest-ever total income at ~₹3,033 crore, EBITDA at ₹601 crore (margin 20.4%), and an all-time high Profit After Tax (PAT) of ₹420 crore. Growth was propelled by new product launches, particularly in Australia and the UK, and market expansion into Germany, Canada, and Ireland.
Marksans Pharma Delivers Historic FY26 Results
Marksans Pharma Ltd. has reported a landmark year for fiscal year 2026, achieving its highest-ever total income, EBITDA, and Profit After Tax (PAT). The company’s financial performance for the quarter and full year ended March 31, 2026, showcased significant growth and operational success. Total income reached approximately ₹3,033 crore, representing a 12.8% increase year-over-year. The EBITDA stood at ₹601 crore with a healthy margin of 20.4%, and PAT hit an all-time high of ₹420 crore, up 9.8% from the previous year.
Key Growth Drivers and Market Expansion
The robust growth in FY26 was attributed to a strategic series of new product launches across various markets. The company’s branded portfolio in Australia saw significant contributions, while the UK market experienced a strong recovery, achieving its highest-ever quarterly revenue in Q4 FY26. Further bolstering growth, Marksans Pharma launched 112 new SKUs in the US market. The company also successfully expanded its global footprint by entering new markets including Germany, Canada, and Ireland.
Strong Financial Position and Outlook
Marksans Pharma concluded the fiscal year with a strong cash balance of approximately ₹990 crore, continuing its multi-year track record of being net cash positive. The company noted that its major capital expenditure cycle is nearing completion. While monitoring input cost pressures, Marksans Pharma expressed confidence in its underlying momentum, balance sheet strength, and disciplined execution to continue delivering sustainable growth and long-term shareholder value.
Q4 FY26 Performance Highlights
In the fourth quarter of FY26 (Q4FY26), Marksans Pharma reported a total income of ₹891 crore, a substantial increase of 23.1% compared to the same period last year. Gross profit stood at ₹466 crore, up 21.5% with a gross margin of 54.4%. EBITDA for the quarter was ₹195 crore, and Earnings Per Share (EPS) was ₹3.3.
Business Segment Performance
The US & North America Formulation business reported revenues of ₹1,533 crore for FY26, a 24.0% increase year-over-year, contributing 52.0% to the total revenue. The UK and Europe segment generated ₹1,015 crore in FY26, despite a slight year-over-year decrease of 1.4%, it still represents a significant 34.4% of total revenue. Australia & New Zealand saw revenues of ₹303 crore in FY26, marking a 19.9% increase and accounting for 10.3% of total revenue. The Rest of World (ROW) market contributed ₹99 crore in FY26, a decrease of 4.1%, making up 3.4% of total revenue.
Key Operational and Financial Metrics (FY26 vs FY25)
Total Income: ₹2,950.9 crore (up 12.5%)
Gross Profit: ₹1,673.7 crore (up 13.2%)
EBITDA: ₹600.8 crore (up 12.8%)
PAT: ₹420.1 crore (up 9.8%)
EPS: ₹9.2 (up 9.8%)
Other Business Highlights
The company’s revenue demonstrated strong growth, scaling 2.4x from FY22 to FY26. Marksans Pharma boasts a robust product engine with over 100 products manufactured and distributed, and an additional 51 products in the pipeline. The UK and Europe market saw multiple new product launches and improved order flow in Q4FY26, with price erosion stabilizing. The Australia and New Zealand business reported its highest-ever quarterly performance in Q4FY26, driven by new launches and volume growth. The company also launched its Branded Prescription Division, Nova Pharma, under which 11 Rx brands were introduced in FY26.
Earnings Conference Call Details
Marksans Pharma Ltd. will host an earnings conference call on May 27, 2026, at 4:30 pm IST. The leadership team will discuss the financial performance and address questions. A transcript of the call will be available on www.marksanspharma.com.
Source: BSE
